Focus:
Cardiovascular
-
11 February 2019 News
Regeneron and Sanofi cut US list price of Praluent
Regeneron and Sanofi have announced they have lowered the list price of high cholesterol drug Praluent (alirocumab) in the US by approximately 60%.
-
25 January 2019 whitepapers
Case Study: Bristol-Myers Squibb
Bristol-Myers Squibb (BMS) is a global biopharmaceutical company headquartered in New York City that specialises in discovering, developing and delivering innovative medicines for patients with serious diseases.
-
28 November 2018 News
Roche subsidiary Genentech to acquire Jecure Therapeutics
Swiss firm Roche Group’s affiliate Genentech has agreed to acquire US biotechnology company Jecure Therapeutics to strengthen its position in the treatment of liver diseases.
-
20 November 2018 Analysis
Is a lack of female participants skewing heart disease trial results?
Heart disease is one of the leading causes of death in men and women, but women are commonly underrepresented in clinical trials. Could this negatively impact the treatment of female...
-
5 October 2018 Comment
Modest growth expected in Asia-Pacific heart failure therapeutics market
The Asia-Pacific market for heart failure therapeutics was estimated at $733.7 million in 2017 and is projected to reach $1,435.9 million in 2024, increasing at a compound annual growth rate...
-
20 September 2018 projects
Boehringer Ingelheim’s New Tablet Production Facility, Ingelheim
Germany-based pharmaceutical company, Boehringer Ingelheim, is constructing a new tablet production facility in Ingelheim, Germany, with an estimated investment of more than €85m ($97.2m).
-
18 September 2018 News
Study finds daily aspirin does not reduce heart attack risk
Monash University in Australia has reported initial results from a large clinical trial (ASPREE) performed to investigate the benefits and risks of low, daily doses of aspirin in healthy people...
-
28 August 2018 News
Pfizer reports data from tafamidis’ rare heart disease trial
A new phase III clinical trial has demonstrated that Pfizer’s tafamidis drug can lower the risk of death in patients suffering from rare heart condition transthyretin amyloid cardiomyopathy.
-
10 August 2018 projects
Amgen’s New Bio-manufacturing Plant, Rhode Island, US
US-based biopharmaceutical company Amgen is developing a bio-manufacturing facility at its campus in West Greenwich, Rhode Island, US.
-
3 July 2018 News
Bayer and Broad Institute expand heart therapy collaboration
The Broad Institute of MIT and Harvard have expanded its strategic partnership with Bayer to launch the new Precision Cardiology Laboratory (PCL), which focuses on developing new therapeutics for heart...